Abstract | BACKGROUND: OBJECTIVE: STUDY DESIGN: Randomized, controlled trial. SETTING: Pain Clinic in Japan. METHODS: Thirty-seven cancer patients, confirmed to have bone metastases, were allocated into 3 groups: P group took pregabalin 50 mg every 8 hours orally; P-I group took pregabalin 25 mg every 8 hours orally and imipramine 5 mg every 12 hours orally; P-M group took pregabalin 25 mg every 8 hours orally and mirtazapine 7.5 mg every 12 hours orally. Pain assessments were performed for 2 weeks. RESULTS: The total pain score significantly decreased in all 3 groups even one day after the start of the medication. The decreases in the P-I and P-M groups were significantly greater than those in the P group from Day 2. Also, the daily paroxysmal pain episodes significantly decreased in all 3 groups at Day one. The decreases in the P-M groups were significantly greater than those in the P group from Day one. The decreases in the P-I group were significantly greater than those in the P group from Day 3. CONCLUSION:
|
Authors | Makota Nishihara, Young-Chang P Arai, Yoshihiro Yamamoto, Kikuyo Nishida, Maki Arakawa, Takahiro Ushida, Masahiko Ikeuchi |
Journal | Pain physician
(Pain Physician)
2013 Sep-Oct
Vol. 16
Issue 5
Pg. E547-52
ISSN: 2150-1149 [Electronic] United States |
PMID | 24077205
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Analgesics, Opioid
- Antidepressive Agents
- Pregabalin
- gamma-Aminobutyric Acid
|
Topics |
- Adult
- Aged
- Analgesics, Opioid
(administration & dosage, therapeutic use)
- Antidepressive Agents
(therapeutic use)
- Bone Neoplasms
(complications, drug therapy, secondary)
- Drug Therapy, Combination
(methods)
- Female
- Humans
- Male
- Middle Aged
- Pain
(drug therapy, etiology)
- Pain Measurement
- Pregabalin
- Treatment Outcome
- gamma-Aminobutyric Acid
(administration & dosage, analogs & derivatives, therapeutic use)
|